Migraine Trust Abstracts – London (September 2006)

• Optimizing Efficacy in the Acute Treatment of Migraine: Evaluation of the Clinical Benefits of Treatment Paradigm and Combination Therapy (Fixed Single-Tablet Formulation of Sumatriptan 85mg RT Technology™ and Naproxen Sodium 500mg, SumaRT/Nap)
• Early Sumatriptan Pharmacokinetics Following a Sumatriptan 100mg RT Technology™ Tablet and a Fixed Single-Tablet Formulation of Sumatriptan 85mg RT Technology™ and 500 MG Naproxen Sodium
• Consistent Efficacy and Tolerability Across Four Migraine Attacks of a Fixed Single-Table Formulation of Sumatriptan 85mg RT Technology™ and Naproxen Sodium 500mg (SumaRT/Nap)

AHS Meeting – Los Angeles (June 2006)

• A New Migraine Therapy: Efficacy and Tolerability of a Fixed Single-Tablet Formulation of Sumatriptan RT Technology™ and Naproxen Sodium in the Early Intervention Paradigm

First Albany Pain Conference (March 2006)

• Podium Presentation: Designing a Safer NSAID

American College of Gastroenterology Annual Meeting

Honolulu, Hawaii (November 2005)

• Podium Presentation: PN 100-103

Headache Magazine (September 2005) article by Dr. Timothy R. Smith

• Research Submission: Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine

Poster Presentations at the 2005 AHS 47th Annual Scientific Meeting (June 2005)

• Evidence For A Role of Dopamine In Migraine ?
• Pharmacokinetic Profile Of Sumatriptan RT Technology and Naproxem Sodium - New Single-tablet Formulation

Poster Presentations at the XI Congress of the International Headache Society (September 2003)

• Time Course of Symptom Relief with Various Anti-migraine Therapies

Poster Presentations at the 2003 AHS 45th Annual Scientific Meeting (June 2003)

• Defining and Analyzing Meaningful Relief in Clinical Trials of Acute Migraine Headache

Poster Presentations at the 2003 American College of Clinical Pharmacy Scientific Meeting (November 2003)

• Over-encapsulated Imitrex 50 mg Tablets are Bioequivalent to Marketed Imitrex 50 mg Tablets